RIPK1 and lysosomal storage disease: Work in the Gaucher disease model demonstrated potential efficacy of RIP3 inhibition.22 Given that the pathological processes leading to neuronal loss in lysosomal storage disorders are often nonspecific, we postulate that RIP1 or combined RIP1/RIP3 inhibition may also prove effective in significantly delaying neurodegeneration in other lysosomal storage disorders.